Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients.

Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P.

BMC Anesthesiol. 2019 Oct 11;19(1):180. doi: 10.1186/s12871-019-0856-x.

2.

Safety Profile of Opicapone in the Management of Parkinson's Disease.

Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, Soares-da-Silva P.

J Parkinsons Dis. 2019;9(4):733-740. doi: 10.3233/JPD-191593.

PMID:
31498127
3.

Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.

Cabreira V, Soares-da-Silva P, Massano J.

Drugs. 2019 Apr;79(6):593-608. doi: 10.1007/s40265-019-01098-w.

PMID:
30905034
4.

Acute salt loading induces sympathetic nervous system overdrive in mice lacking salt-inducible kinase 1 (SIK1).

Pires NM, Igreja B, Serrão MP, Matias EF, Moura E, António T, Campos FL, Brion L, Bertorello A, Soares-da-Silva P.

Hypertens Res. 2019 Aug;42(8):1114-1124. doi: 10.1038/s41440-019-0249-z. Epub 2019 Mar 20.

PMID:
30894696
5.

Effects of nepicastat upon dopamine-β-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland.

Catelas DN, Serrão MP, Soares-Da-Silva P.

Clin Exp Hypertens. 2019 Mar 1:1-8. doi: 10.1080/10641963.2019.1583245. [Epub ahead of print]

PMID:
30821508
6.

Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6.

Silva T, Mohamed T, Shakeri A, Rao PPN, Soares da Silva P, Remião F, Borges F.

Eur J Med Chem. 2019 Apr 1;167:146-152. doi: 10.1016/j.ejmech.2019.02.006. Epub 2019 Feb 4.

PMID:
30771602
7.

Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.

Pinheiro SD, Serrão MP, Silva T, Borges F, Soares-da-Silva P.

Eur J Pharmacol. 2019 Mar 15;847:53-60. doi: 10.1016/j.ejphar.2019.01.027. Epub 2019 Jan 24.

PMID:
30685433
8.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.

9.

Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure.

Igreja B, Pires NM, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2019 Jan 5;842:125-132. doi: 10.1016/j.ejphar.2018.10.030. Epub 2018 Oct 26.

PMID:
30401628
10.

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P.

Drugs Aging. 2018 Dec;35(12):1109-1117. doi: 10.1007/s40266-018-0602-y.

11.

Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.

Kitajima T, Mizote S, Bonifácio MJ, Umemura T, Yoneda K, Moser P, Soares-da-Silva P, Tanaka M.

Neuropharmacology. 2018 Dec;143:282-288. doi: 10.1016/j.neuropharm.2018.10.001. Epub 2018 Oct 2.

12.

Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.

Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P.

ChemMedChem. 2018 Oct 22;13(20):2177-2188. doi: 10.1002/cmdc.201800393. Epub 2018 Sep 11.

13.

Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells.

Holtkamp D, Opitz T, Hebeisen S, Soares-da-Silva P, Beck H.

Epilepsia. 2018 Aug;59(8):1492-1506. doi: 10.1111/epi.14504. Epub 2018 Jun 28.

14.

Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy.

Beckonert NM, Opitz T, Pitsch J, Soares da Silva P, Beck H.

J Neurosci. 2018 Jun 13;38(24):5596-5605. doi: 10.1523/JNEUROSCI.0640-18.2018. Epub 2018 May 22.

15.

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Gidal BE, Jacobson MP, Ben-Menachem E, Carreño M, Blum D, Soares-da-Silva P, Falcão A, Rocha F, Moreira J, Grinnell T, Ludwig E, Fiedler-Kelly J, Passarell J, Sunkaraneni S.

Acta Neurol Scand. 2018 Sep;138(3):203-211. doi: 10.1111/ane.12950. Epub 2018 May 6.

16.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P.

Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.

PMID:
29695590
17.

Eslicarbazepine acetate exposure in pregnant women with epilepsy.

Costa R, Magalhães LM, Graça J, Vieira M, Gama H, Moreira J, Rocha JF, Soares-da-Silva P.

Seizure. 2018 May;58:72-74. doi: 10.1016/j.seizure.2018.04.007. Epub 2018 Apr 10. Review.

18.

Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice.

Armando I, Asico LD, Wang X, Jones JE, Serrão MP, Cuevas S, Grandy DK, Soares-da-Silva P, Jose PA.

Hypertens Res. 2018 Jul;41(7):489-498. doi: 10.1038/s41440-018-0041-5. Epub 2018 Apr 13.

19.
20.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.

Epilepsy Behav. 2018 Apr;81:1-11. doi: 10.1016/j.yebeh.2018.01.029. Epub 2018 Feb 22.

21.

In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.

Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Eur J Pharm Sci. 2018 May 30;117:35-40. doi: 10.1016/j.ejps.2018.02.006. Epub 2018 Feb 8.

PMID:
29428540
22.

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, Rocha JF, Soares-da-Silva P.

Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25.

23.

Reliability of body-weight scalars on the assessment of propofol induction dose in obese patients.

Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P.

Acta Anaesthesiol Scand. 2018 Apr;62(4):464-473. doi: 10.1111/aas.13039. Epub 2017 Nov 21.

PMID:
29159892
24.

Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.

Krauss G, Biton V, Harvey JH, Elger C, Trinka E, Soares da Silva P, Gama H, Cheng H, Grinnell T, Blum D.

Epilepsy Res. 2018 Jan;139:1-8. doi: 10.1016/j.eplepsyres.2017.10.021. Epub 2017 Nov 4.

25.

Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.

Elger C, Koepp M, Trinka E, Villanueva V, Chaves J, Ben-Menachen E, Kowacs PA, Gil-Nagel A, Moreira J, Gama H, Rocha JF, Soares-da-Silva P.

CNS Neurosci Ther. 2017 Dec;23(12):961-972. doi: 10.1111/cns.12765. Epub 2017 Oct 13.

26.

Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors.

Bicker J, Fortuna A, Alves G, Soares-da-Silva P, Falcão A.

Drug Metab Dispos. 2017 Dec;45(12):1282-1291. doi: 10.1124/dmd.117.077883. Epub 2017 Sep 15.

PMID:
28916530
27.

The effect of PRR ligands on the membrane potential of intestinal epithelial cells.

Magalhães D, Soares-da-Silva P, Magro F.

Pharmacol Rep. 2017 Oct;69(5):978-984. doi: 10.1016/j.pharep.2017.04.010. Epub 2017 Apr 23.

PMID:
28837901
28.

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.

Gama H, Vieira M, Costa R, Graça J, Magalhães LM, Soares-da-Silva P.

Drug Saf. 2017 Dec;40(12):1231-1240. doi: 10.1007/s40264-017-0576-4. Review.

29.

A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.

Gonçalves D, Alves G, Fortuna A, Bonifácio MJ, Soares-da-Silva P, Falcão A.

Neuropharmacology. 2017 Oct;125:146-155. doi: 10.1016/j.neuropharm.2017.07.019. Epub 2017 Jul 19.

PMID:
28734868
30.

Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply.

Lees AJ, Rocha JF, Soares-da-Silva P.

JAMA Neurol. 2017 Jul 1;74(7):873. doi: 10.1001/jamaneurol.2017.0726. No abstract available.

PMID:
28531266
31.

Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Toxicol Appl Pharmacol. 2017 May 15;323:9-15. doi: 10.1016/j.taap.2017.03.013. Epub 2017 Mar 16.

PMID:
28322896
32.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators.

JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.

PMID:
28027332
33.

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Rocha JF, Sicard É, Fauchoux N, Falcão A, Santos A, Loureiro AI, Pinto R, Bonifácio MJ, Nunes T, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2017 Mar;83(3):540-553. doi: 10.1111/bcp.13156. Epub 2016 Dec 2.

34.

Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.

Silva T, Mohamed T, Shakeri A, Rao PP, Martínez-González L, Pérez DI, Martínez A, Valente MJ, Garrido J, Uriarte E, Serrão P, Soares-da-Silva P, Remião F, Borges F.

J Med Chem. 2016 Aug 25;59(16):7584-97. doi: 10.1021/acs.jmedchem.6b00666. Epub 2016 Aug 5.

PMID:
27463695
35.

Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.

Rocha JF, Ferreira JJ, Falcão A, Santos A, Pinto R, Nunes T, Almeida L, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2016 May;5(3):232-40. doi: 10.1002/cpdd.217. Epub 2015 Oct 20.

PMID:
27163503
36.

Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.

Falcão A, Rocha JF, Santos A, Nunes T, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2016 Mar;5(2):150-61. doi: 10.1002/cpdd.213. Epub 2015 Oct 16.

PMID:
27138028
37.

Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.

Pinto R, l'Hostis P, Patat A, Homery MC, Falcão A, Nunes T, Rocha JF, Soares-da-Silva P.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):454-62. doi: 10.1002/cpdd.188. Epub 2015 May 7.

PMID:
27137718
38.

A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.

Bicker J, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Int J Pharm. 2016 Mar 30;501(1-2):102-11. doi: 10.1016/j.ijpharm.2016.01.074. Epub 2016 Feb 1.

PMID:
26836708
39.

Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.

Igreja B, Wright LC, Soares-da-Silva P.

J Am Soc Hypertens. 2016 Mar;10(3):207-16. doi: 10.1016/j.jash.2015.12.011. Epub 2015 Dec 19.

PMID:
26803288
40.

Role of epithelial ion transports in inflammatory bowel disease.

Magalhães D, Cabral JM, Soares-da-Silva P, Magro F.

Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G460-76. doi: 10.1152/ajpgi.00369.2015. Epub 2016 Jan 7. Review.

41.

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators.

Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.

PMID:
26725544
42.

Amine neurotransmitters, inflammation and epithelial sodium transport.

Soares-da-Silva P, Cabral JM, Magalhães D, Fraga S, Magro F.

Exp Physiol. 2016 Apr;101(4):459-64. doi: 10.1113/EP085284. Epub 2015 Dec 14. Review.

43.

Carbamazepine aggravates absence seizures in two dedicated mouse models.

Pires NM, Bonifácio MJ, Soares-da-Silva P.

Pharmacol Rep. 2015 Oct;67(5):986-95. doi: 10.1016/j.pharep.2015.03.007. Epub 2015 Mar 23.

PMID:
26398395
44.

Short- and long-term regulation of intestinal Na+/H+ exchange by Toll-like receptors TLR4 and TLR5.

Cabral JM, Grácio D, Soares-da-Silva P, Magro F.

Am J Physiol Gastrointest Liver Physiol. 2015 Oct 15;309(8):G703-15. doi: 10.1152/ajpgi.00124.2015. Epub 2015 Aug 20.

45.

Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Biomed Chromatogr. 2016 Mar;30(3):312-22. doi: 10.1002/bmc.3550. Epub 2015 Aug 17.

PMID:
26147707
46.

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.

Soares-da-Silva P, Pires N, Bonifácio MJ, Loureiro AI, Palma N, Wright LC.

Pharmacol Res Perspect. 2015 Mar;3(2):e00124. doi: 10.1002/prp2.124. Epub 2015 Mar 30. Review.

47.

Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Pires N, Igreja B, Wright LC, Soares-da-Silva P.

Xenobiotica. 2015;45(9):828-39. doi: 10.3109/00498254.2015.1018985. Epub 2015 Jun 10.

PMID:
25915108
48.

Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey.

Loureiro AI, Soares-da-Silva P.

Xenobiotica. 2015;45(10):903-11. doi: 10.3109/00498254.2015.1024780. Epub 2015 Apr 14.

PMID:
25869244
49.

Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.

Pires NM, Igreja B, Moura E, Wright LC, Serrão MP, Soares-da-Silva P.

Hypertens Res. 2015 Sep;38(9):605-12. doi: 10.1038/hr.2015.50. Epub 2015 Apr 9.

PMID:
25854989
50.

Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors.

Booker SA, Pires N, Cobb S, Soares-da-Silva P, Vida I.

Neuropharmacology. 2015 Jun;93:103-15. doi: 10.1016/j.neuropharm.2015.01.019. Epub 2015 Feb 3.

PMID:
25656478

Supplemental Content

Loading ...
Support Center